Start With the Basics: What Is Growth Hormone?
Growth hormone (GH) is produced by the pituitary gland and is one of the most important metabolic regulators in the human body. It influences muscle mass, fat metabolism, bone density, sleep quality, recovery speed, and — through its downstream effects on IGF-1 — cellular repair throughout the body.
GH levels peak in your late teens and decline steadily from your mid-20s onward. By the time most people reach their 40s, they are producing significantly less GH than they did in their 20s. This decline is associated with changes in body composition, recovery capacity, and energy levels that most people simply accept as normal aging.
The research question CJC-1295 and Ipamorelin address is: can you stimulate the body’s own GH production rather than replacing it with synthetic GH injections?
CJC-1295: Amplifying the Signal
Your body releases GH in response to a signal from the hypothalamus called Growth Hormone Releasing Hormone (GHRH). CJC-1295 is a modified synthetic analog of GHRH — it binds to the same receptor in the pituitary gland that GHRH binds to, triggering GH release.
The key modification is the DAC (Drug Affinity Complex) addition, which allows CJC-1295 to bind to albumin (a protein in your blood) and be released slowly over time. Native GHRH has a half-life of just a few minutes. CJC-1295 with DAC has a half-life measured in days in animal studies, meaning a single dose can maintain elevated GH-stimulating activity for an extended period.
In clinical research, CJC-1295 has been shown to increase GH and IGF-1 levels in human subjects — one of the few peptides in this category with actual human clinical data, though studies are small and primarily dose-finding rather than outcomes-based.
Ipamorelin: Selectively Pulling the Trigger
Ipamorelin works differently. Rather than mimicking GHRH, it mimics a compound called ghrelin and acts on the Growth Hormone Secretagogue Receptor (GHSR) — a different pathway that also triggers GH release from the pituitary.
What makes Ipamorelin particularly interesting is its selectivity. Earlier compounds in the same class (GHRPs) triggered not just GH release but also significant spikes in cortisol and prolactin — stress and reproductive hormones that you generally do not want elevated. Ipamorelin was specifically developed to minimize this off-target activity. Animal studies confirm that Ipamorelin produces meaningful GH release with minimal cortisol or prolactin stimulation.
Why They Work Better Together
CJC-1295 acts on the GHRH receptor and increases the amplitude of GH pulses — how much GH is released each time. Ipamorelin acts on the GHSR receptor and increases the frequency of GH pulses — how often release occurs. These are additive effects through non-overlapping mechanisms.
Animal studies combining both compounds showed greater total GH and IGF-1 output than either compound alone — not double, but synergistically higher. This is the scientific rationale behind pairing them, and it is mechanistically sound.
Current Availability
Both CJC-1295 and Ipamorelin are available through licensed 503A compounding pharmacies with a physician prescription. They are among the compounds My Body Labs plans to include in the Performance protocol following the July 2026 FDA PCAC review.